Skip to main content
padlock icon - secure page this page is secure

CGRP, Amylin, Immunology, and Headache Medicine

Buy Article:

$52.00 + tax (Refund Policy)

Calcitonin gene‐related peptide (CGRP) therapeutics introduce new excitement and possibly yet to be determined distressing discords in the field of Headache Medicine. Growth in knowledge of CGRP in the pathophysiology of migraine introduced CGRP antagonism to headache treatment. Potential adverse effects on the other circulatory and neurovascular diseases have been foremost concerns. Failures in development of gepants and growth in knowledge of monoclonal antibody therapeutics combined to deliver the anti‐CGRP monoclonal antibodies (mAbs).
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: CGRP antagonism; amylin; calcitonin gene‐related peptide; cell surface G protein receptors; hybridoma; monoclonal antibodies

Document Type: Research Article

Publication date: January 1, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more